Thyroid Hormone Receptor Agonists Reduce Serum Cholesterol Independent of the LDL Receptor.
Endocrinology., Dec;153(12):6136-44 (2012)
Distinct ligand-dependent and independent modes of thyroid hormone receptor (TR)/PGC-1Î± interaction.
J. Steroid Biochem. Mol. Biol., Jan;133:58-65 (2013)
Allosteric conversation in the androgen receptor ligand-binding domain surfaces.
Mol. Endocrinol., Jul;26(7):1078-90 (2012)
GQ-16, a novel peroxisome proliferator-activated receptor Î³ (PPARÎ³) ligand, promotes insulin sensitization without weight gain.
J. Biol. Chem., Aug;287(33):28169-79 (2012)
Research resource: The estrogen receptor Î± cistrome defined by DamIP.
Mol. Endocrinol., Feb;26(2):349-57 (2012)
Structural basis of coactivation of liver receptor homolog-1 by Î²-catenin.
Proc. Natl. Acad. Sci. U.S.A., Jan;109(1):143-8 (2012)
Estrogenic plant extracts reverse weight gain and fat accumulation without causing mammary gland or uterine proliferation.
PLoS ONE., 6(12):e28333 (2011)
Identical gene regulation patterns of T3 and selective thyroid hormone receptor modulator GC-1.
Endocrinology., Jan;153(1):501-11 (2012)
A peroxisome proliferator-activated receptor gamma (PPARgamma)/PPARgamma coactivator 1beta autoregulatory loop in adipocyte mitochondrial function.
J. Biol. Chem., Sep;286(35):30723-31 (2011)
Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score.
Antivir. Ther. (Lond.)., 15(7):1011-9 (2010)
Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.
Hepatology., Dec;52(6):2001-11 (2010)
Susceptibility of HIV-1 to tipranavir and other antiretroviral agents in treatment-experienced patients: The UTILIZE Study.
Curr. HIV Res., Jun;8(4):347-54 (2010)
Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia.
N. Engl. J. Med., Mar;362(10):906-16 (2010)
Gaining ligand selectivity in thyroid hormone receptors via entropy.
Proc. Natl. Acad. Sci. U.S.A., Dec;106(49):20717-22 (2009)
Identification of CCR4 and other essential thyroid hormone receptor co-activators by modified yeast synthetic genetic array analysis.
Proc. Natl. Acad. Sci. U.S.A., Nov;106(47):19854-9 (2009)
Differential effects of TR ligands on hormone dissociation rates: evidence for multiple ligand entry/exit pathways.
J. Steroid Biochem. Mol. Biol., Nov;117(4-5):125-31 (2009)
Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes.
Nat Rev Drug Discov., Apr;8(4):308-20 (2009)
Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
J. Infect. Dis., Mar;199(5):693-701 (2009)
Complex actions of thyroid hormone receptor antagonist NH-3 on gene promoters in different cell lines.
Mol. Cell. Endocrinol., Dec;296(1-2):69-77 (2008)
Molecular basis for dimer formation of TRbeta variant D355R.
Proteins., Apr;75(1):111-7 (2009)
Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141.
J. Steroid Biochem. Mol. Biol., Sep;111(3-5):262-7 (2008)
Quantification of ligand-regulated nuclear receptor corepressor and coactivator binding, key interactions determining ligand potency and efficacy for the thyroid hormone receptor.
Biochemistry., Jul;47(28):7465-76 (2008)
Protease inhibitor resistance update: where are we now?
AIDS Patient Care STDS., Apr;22(4):267-77 (2008)
Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.
J. Acquir. Immune Defic. Syndr., May;48(1):26-34 (2008)
Cardiovascular and metabolic issues in patients with thyroid dysfunction will be highlighted at the Fifth Anniversary of ATA Spring Meetings in March 2008.
Thyroid., Feb;18(2):101 (2008)
Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms.
BMC Struct. Biol., 8:8 (2008)
The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans.
Proc. Natl. Acad. Sci. U.S.A., Jan;105(2):663-7 (2008)
The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naÃ¯ve participants started on three different antiretroviral therapy strategies.
HIV Clin Trials., 8(6):357-70 (2007 Nov-Dec)
A surface on the androgen receptor that allosterically regulates coactivator binding.
Proc. Natl. Acad. Sci. U.S.A., Oct;104(41):16074-9 (2007)
Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor.
Mol. Endocrinol., Dec;21(12):2919-28 (2007)
Thyroid hormone response element organization dictates the composition of active receptor.
J. Biol. Chem., Apr;282(17):12458-66 (2007)
Low-resolution structures of thyroid hormone receptor dimers and tetramers in solution.
Biochemistry., Feb;46(5):1273-83 (2007)
The experts speak. New issues in the challenge of HIV drug resistance. Interview by Vicki Glaser.
AIDS Patient Care STDS., Nov;20(11):737-40 (2006)
International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors.
Pharmacol. Rev., Dec;58(4):705-11 (2006)
Corepressor/coactivator paradox: potential constitutive coactivation by corepressor splice variants.
Nucl Recept Signal., 4:e022 (2006)
Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study.
J. Acquir. Immune Defic. Syndr., Oct;43(2):169-78 (2006)
Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.
J. Virol., Nov;80(21):10794-801 (2006)
Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
Antivir. Ther. (Lond.)., 11(4):457-63 (2006)
A high-throughput screening method to identify small molecule inhibitors of thyroid hormone receptor coactivator binding.
Sci. STKE., Jun;2006(341):pl3 (2006)
Structural rearrangements in the thyroid hormone receptor hinge domain and their putative role in the receptor function.
J. Mol. Biol., Jul;360(3):586-98 (2006)
Human thyroid receptor forms tetramers in solution, which dissociate into dimers upon ligand binding.
Cell Biochem. Biophys., 44(3):453-62 (2006)
Metabolism: bile acids heat things up.
Nature., Jan;439(7075):402-3 (2006)
Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators.
J. Biol. Chem., Dec;280(52):43048-55 (2005)
Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.
HIV Clin Trials., 6(3):127-35 (2005 May-Jun)
Different configurations of specific thyroid hormone response elements mediate opposite effects of thyroid hormone and GC-1 on gene expression.
Endocrinology., Nov;146(11):4926-33 (2005)
Molecular dynamics simulations reveal multiple pathways of ligand dissociation from thyroid hormone receptors.
Biophys. J., Sep;89(3):2011-23 (2005)
Rearrangements in thyroid hormone receptor charge clusters that stabilize bound 3,5',5-triiodo-L-thyronine and inhibit homodimer formation.
J. Biol. Chem., Jul;280(27):25665-73 (2005)
Conformational adaptation of nuclear receptor ligand binding domains to agonists: potential for novel approaches to ligand design.
J. Steroid Biochem. Mol. Biol., Feb;93(2-5):127-37 (2005)
E1A and a nuclear receptor corepressor splice variant (N-CoRI) are thyroid hormone receptor coactivators that bind in the corepressor mode.
Proc. Natl. Acad. Sci. U.S.A., May;102(18):6267-72 (2005)
Hammett analysis of selective thyroid hormone receptor modulators reveals structural and electronic requirements for hormone antagonists.
J. Am. Chem. Soc., Apr;127(13):4599-608 (2005)
Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.
Clin. Infect. Dis., Feb;40(3):468-74 (2005)
The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor.
J. Biol. Chem., Mar;280(9):8060-8 (2005)
Thyroxine-thyroid hormone receptor interactions.
J. Biol. Chem., Dec;279(53):55801-8 (2004)
Thyroid hormone transport is disturbed in erythrocytes from patients with chronic renal failure on hemodialysis.
Ren Fail., Jul;26(4):461-6 (2004)
Towards selectively modulating mineralocorticoid receptor function: lessons from other systems.
Mol. Cell. Endocrinol., Mar;217(1-2):151-65 (2004)
Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight.
Trends Endocrinol. Metab., 15(4):154-7 (2004 May-Jun)
Both thyroid hormone receptor (TR)beta 1 and TR beta 2 isoforms contribute to the regulation of hypothalamic thyrotropin-releasing hormone.
Endocrinology., May;145(5):2337-45 (2004)
Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine.
Endocrinology., Apr;145(4):1656-61 (2004)
Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor.
Proc. Natl. Acad. Sci. U.S.A., Dec;100(26):15358-63 (2003)
ERbeta Binds N-CoR in the Presence of Estrogens via an LXXLL-like Motif in the N-CoR C-terminus.
Nucl. Recept., Jun;1(1):4 (2003)
Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability.
Proc. Natl. Acad. Sci. U.S.A., Aug;100(17):10067-72 (2003)
Structural determinants of selective thyromimetics.
J. Med. Chem., Jul;46(14):3152-61 (2003)
Design of thyroid hormone receptor antagonists from first principles.
J. Steroid Biochem. Mol. Biol., Dec;83(1-5):59-73 (2002)
Low resolution structures of the retinoid X receptor DNA-binding and ligand-binding domains revealed by synchrotron X-ray solution scattering.
J. Biol. Chem., May;278(18):16030-8 (2003)
Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment.
J. Med. Chem., Jul;45(15):3310-20 (2002)
Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy.
AIDS., May;16(8):1131-8 (2002)
TR surfaces and conformations required to bind nuclear receptor corepressor.
Mol. Endocrinol., Feb;16(2):271-86 (2002)
Longitudinal observations (1987-1997) on the prevalence of middle ear disease and associated risk factors among Inuit children of Inukjuak, Nunavik, Quebec, Canada.
Int J Circumpolar Health., Nov;60(4):632-9 (2001)
Hormone selectivity in thyroid hormone receptors.
Mol. Endocrinol., Mar;15(3):398-410 (2001)
Chronic disseminated infection and intravesical bacillus Calmette-Guerin.
N J Med., Jan;96(1):50-2 (1999)
X-ray crystallographic and functional studies of thyroid hormone receptor.
J. Steroid Biochem. Mol. Biol., Apr;65(1-6):133-41 (1998)
DAX1 mutations map to putative structural domains in a deduced three-dimensional model.
Am. J. Hum. Genet., Apr;62(4):855-64 (1998)
The history of otolaryngology in Canada: University of Alberta.
J Otolaryngol., Apr;27(2):115-9 (1998)
The history of otolaryngology in Canada: University of Montreal.
J Otolaryngol., Feb;27(1):55-60 (1998)
The history of otolaryngology in Canada: Dalhousie University.
J Otolaryngol., Oct;26(5):351-5 (1997)